The estimated Net Worth of John J Kuch is at least $7.66 Million dollars as of 11 March 2024. Mr. Kuch owns over 849 units of Xencor Inc stock worth over $2,558,209 and over the last 11 years he sold XNCR stock worth over $3,524,317. In addition, he makes $1,580,080 as Chief Financial Officer and Vice President at Xencor Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Kuch XNCR stock SEC Form 4 insiders trading
John has made over 21 trades of the Xencor Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 849 units of XNCR stock worth $19,952 on 11 March 2024.
The largest trade he's ever made was exercising 50,000 units of Xencor Inc stock on 24 June 2016 worth over $29,500. On average, John trades about 9,821 units every 113 days since 2013. As of 11 March 2024 he still owns at least 121,070 units of Xencor Inc stock.
You can see the complete history of Mr. Kuch stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John Kuch biography
John J. Kuch serves as Chief Financial Officer, Vice President of the Company. He has served as our Senior Vice President and Chief Financial Officer since May 2018 and served as our Vice President, Finance since October 2010 to May 2018. Mr. Kuch joined the Company in October 2000, serving as our Senior Director of Finance. Mr. Kuch oversees all SEC and financial reporting, budgeting, cash-flow management, investments, information technology, investor relations, capital financing and facility issues for the Company. Mr. Kuch has had primary responsibility for the Company’s initial public offering and its subsequent follow-on financing transactions. Prior to joining us, he worked for over 15 years in public accounting. From August 1997 through December 1998 he served as a Director at PricewaterhouseCoopers LLP. Mr. Kuch is a certified public accountant and received a B.S. and a M.S. in accounting from the University of Illinois.
What is the salary of John Kuch?
As the Chief Financial Officer and Vice President of Xencor Inc, the total compensation of John Kuch at Xencor Inc is $1,580,080. There are 4 executives at Xencor Inc getting paid more, with Bassil Dahiyat having the highest compensation of $3,731,510.
How old is John Kuch?
John Kuch is 60, he's been the Chief Financial Officer and Vice President of Xencor Inc since 2018. There are 5 older and 13 younger executives at Xencor Inc. The oldest executive at Xencor Inc is Richard Ranieri, 67, who is the Independent Director.
What's John Kuch's mailing address?
John's mailing address filed with the SEC is C/O XENCOR, INC., 465 N HALSTEAD STREET, SUITE 200, PASADENA, CA, 91107.
Insiders trading at Xencor Inc
Over the last 11 years, insiders at Xencor Inc have traded over $93,804,287 worth of Xencor Inc stock and bought 1,139,502 units worth $15,515,932 . The most active insiders traders include Capital, Llcstafford John S..., John S Iii Stafford, and John S Jr Stafford. On average, Xencor Inc executives and independent directors trade stock every 23 days with the average trade being worth of $779,296. The most recent stock trade was executed by John R Desjarlais on 9 July 2024, trading 50,000 units of XNCR stock currently worth $536,500.
What does Xencor Inc do?
antibodies by design antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. at xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. our xmab antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. this combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. the xmab® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by xencor and by pharmaceutical partners. xencor is also discovering biologics product
What does Xencor Inc's logo look like?
Complete history of Mr. Kuch stock trades at Xencor Inc
Xencor Inc executives and stock owners
Xencor Inc executives and other stock owners filed with the SEC include:
-
Bassil Dahiyat,
President, Chief Executive Officer, Founder and Director -
Allen Yang,
Senior Vice President, Chief Medical Officer -
Celia Eckert,
Vice President, General Counsel, Corporate Secretary -
John Desjarlais,
Senior Vice President, Research and Chief Scientific Officer -
John Kuch,
Chief Financial Officer, Vice President -
Dr. Bassil I. Dahiyat Ph.D.,
Co-Founder, CEO, Pres & Director -
Dr. Allen S. Yang M.D., Ph.D.,
Sr. VP & Chief Medical Officer -
Dr. John R. Desjarlais,
Sr. VP of Research & Chief Scientific Officer -
Celia E. Eckert J.D.,
Sr. VP, Gen. Counsel & Corp. Sec. -
John J. Kuch,
Sr. VP & CFO -
A. Bruce Montgomery,
Lead Independent Director -
Dagmar Rosa-Bjorkeson,
Independent Director -
Kurt Gustafson,
Independent Director -
Yujiro Hata,
Independent Director -
Richard Ranieri,
Independent Director -
Kevin Gorman,
Independent Director -
Ellen Feigal,
Independent Director -
Julie Casciani,
Executive Director - Human Resources -
Kirk Rosemark,
Vice President, Regulatory Affairs and Quality Assurance -
Eric Kowack,
Vice President, Program Leadership and Strategic Alliances -
Jeremy Grunstein,
Vice President of Business Development -
Kirk Rosemark RAC,
Sr. VP of Regulatory Affairs & Quality Assurance -
Jennifer Sandoz,
VP of HR -
Charles Liles,
Associate Director and Head of Corp. Communications & Investor Relations -
John S Iii Ronin Capital, L...,
-
Paul A Foster,
Chief Medical Officer -
Barbara Klencke,
Director -
Bruce L A Carter,
Director -
Edgardo Jr Baracchini,
Chief Business Officer -
Robert Jr. Baltera,
Director -
Bart Jan Cornelissen,
SR. VICE PRESIDENT & CFO -
John S Jr Stafford,
10% owner -
Trading, Llc Ronin,
10% owner -
Lloyd A Rowland,
Sr. V.P. and General Counsel -
Atul Saran,
Director -
Harold R Werner,
Director -
Jonathan Fleming,
Director -
John S Iii Stafford,
10% owner -
Capital, Llcstafford John S...,
-
Nancy Valente,
EVP, Chief Development Officer